Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus

MT Newswires Live06-22

Eledon Pharmaceuticals (ELDN) said Monday that new long-term mid-stage data showed tegoprubart had sustained higher kidney function and improved patient-reported outcomes in kidney transplant patients than tacrolimus.

At 18 months, tegoprubart-treated patients maintained higher mean estimated glomerular filtration rate over time, the clnical-stage company said.

Eledon said no biopsy-proven acute rejection events occurred in tegoprubart-treated patients after the first six months of treatment, while seven events were reported in the tacrolimus arm after six months.

The company said it plans to begin late-stage development of tegoprubart late this year.

Shares of the company were up more than 2% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645022871?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645022871","market":"sh","top_or_hot":-1,"title":"Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus","media":"MT Newswires Live","content":"<html><body><p> Eledon Pharmaceuticals (ELDN) said Monday that new long-term mid-stage data showed tegoprubart had sustained higher kidney function and improved patient-reported outcomes in kidney transplant patients than tacrolimus.</p><p>At 18 months, tegoprubart-treated patients maintained higher mean estimated glomerular filtration rate over time, the clnical-stage company said.</p><p>Eledon said no biopsy-proven acute rejection events occurred in tegoprubart-treated patients after the first six months of treatment, while seven events were reported in the tacrolimus arm after six months.</p><p>The company said it plans to begin late-stage development of tegoprubart  late this year.</p><p>Shares of the company were up more than 2% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Eledon Pharmaceuticals (ELDN) said Monday that new long-term mid-stage data showed tegoprubart had sustained higher kidney function and improved patient-reported outcomes in kidney transplant patients than tacrolimus.</p><p>At 18 months, tegoprubart-treated patients maintained higher mean estimated glomerular filtration rate over time, the clnical-stage company said.</p><p>Eledon said no biopsy-proven acute rejection events occurred in tegoprubart-treated patients after the first six months of treatment, while seven events were reported in the tacrolimus arm after six months.</p><p>The company said it plans to begin late-stage development of tegoprubart  late this year.</p><p>Shares of the company were up more than 2% in recent Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELDN","symbol_name":"Eledon Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645022871","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645022871","pubTimestamp":1782130817,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eledon Pharmaceuticals  said Monday that new long-term mid-stage data showed tegoprubart had sustained higher kidney function and improved patient-reported outcomes in kidney transplant patients than tacrolimus.At 18 months, tegoprubart-treated patients maintained higher mean estimated glomerular filtration rate over time, the clnical-stage company said.Eledon said no biopsy-proven acute rejection events occurred in tegoprubart-treated patients after the first six months of treatment, while seven events were reported in the tacrolimus arm after six months.The company said it plans to begin late-stage development of tegoprubart  late this year.Shares of the company were up more than 2% in recent Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELDN":"Eledon Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Eledon表示，中期数据显示，与他克莫司相比，Tegoprubart可提供更高的肾功能和改善的结局","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELDN":1},"content_text":"Eledon Pharmaceuticals (ELDN) said Monday that new long-term mid-stage data showed tegoprubart had sustained higher kidney function and improved patient-reported outcomes in kidney transplant patients than tacrolimus.At 18 months, tegoprubart-treated patients maintained higher mean estimated glomerular filtration rate over time, the clnical-stage company said.Eledon said no biopsy-proven acute rejection events occurred in tegoprubart-treated patients after the first six months of treatment, while seven events were reported in the tacrolimus arm after six months.The company said it plans to begin late-stage development of tegoprubart  late this year.Shares of the company were up more than 2% in recent Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645022871","isCrawlerRequest":true}